Recommended dosage is 400 mg orally once daily with food (four 100-mg capsules).
If patients are intolerant to therapy:
Subsequent doses may be reduced to 300 mg orally once daily with food.
Dose may be further reduced to 300 mg once daily with food for 5 consecutive days each week as necessary.
Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity.
Capsules of ZOLINZA should not be opened or crushed.
Instruct patients to drink at least 8 glasses (2 L) of fluids per day to prevent dehydration.

Capsules may not be
shown at actual size.

Selected Important Safety Information

Severe thrombocytopenia and GI bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (eg, valproic acid). Monitor platelet count every 2 weeks for the first 2 months.
Carefully monitor patients concurrently administered ZOLINZA and coumarin derivatives for prolongation of prothrombin time and international normalized ratio.
ZOLINZA was not evaluated in patients with hepatic impairment. Because ZOLINZA is predominantly eliminated through metabolism, treat patients with hepatic impairment with caution.

Before prescribing ZOLINZA, please read the physician Prescribing Information. The Patient Product Information is also available.